Inovio Pharmaceuticals Inc (NASDAQ:INO) has a beta value of 0.73 and has seen 1.01 million shares traded in the recent trading session. The company, currently valued at $71.47M, closed the recent trade at $1.98 per share which meant it lost -$0.17 on the day or -7.91% during that session. The INO stock price is -644.95% off its 52-week high price of $14.75 and -3.03% below the 52-week low of $2.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.76 million shares traded. The 3-month trading volume is 578.20K shares.

The consensus among analysts is that Inovio Pharmaceuticals Inc (INO) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.93.

Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information

Sporting -7.91% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the INO stock price touched $1.98 or saw a rise of 51.47%. Year-to-date, Inovio Pharmaceuticals Inc shares have moved -67.65%, while the 5-day performance has seen it change -50.81%. Over the past 30 days, the shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have changed -53.58%. Short interest in the company has seen 3.5 million shares shorted with days to cover at 11.22.

Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 75.25% from the levels at last check today. The projected low price target is $8.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -304.04% off the targeted high while a plunge would see the stock gain -304.04% from the levels at last check today.

Inovio Pharmaceuticals Inc (INO) estimates and forecasts

Figures show that Inovio Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -76.87% over the past 6 months, with this year growth rate of 26.77%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be -84.30%.

5 analysts offering their estimates for the company have set an average revenue estimate of 30k for the current quarter. 1 have an estimated revenue figure of 100k for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 13.49% over the past 5 years. Earnings growth for 2024 is a modest 28.41% while over the next 5 years, the company’s earnings are expected to increase by 41.50%.

INO Dividends

Inovio Pharmaceuticals Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders

Insiders own 0.85% of the company shares, while shares held by institutions stand at 33.51% with a share float percentage of 33.80%. Investors are also buoyed by the number of investors in a company, with Inovio Pharmaceuticals Inc having a total of 129.0 institutions that hold shares in the company.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Sep 30, 2024, the former fund manager holds about 3.14% shares in the company for having 818.82 shares of worth $1.58 million while later fund manager owns 688.82 shares of worth $1.33 million as of Sep 30, 2024, which makes it owner of about 2.64% of company’s outstanding stock.